NCT04745533 (DETAC) is a clinical trial of Antigen detection test in SARS-CoV Infection, sponsored by Juan Fernando Masa Jiménez.

Who is sponsoring NCT04745533?

NCT04745533 is sponsored by Juan Fernando Masa Jiménez.

What drugs are being tested in NCT04745533?

Interventions in NCT04745533: Antigen detection test.

What condition does NCT04745533 study?

NCT04745533 studies SARS-CoV Infection.

Is NCT04745533 still recruiting?

NCT04745533 is currently status unknown. Last updated 11 February 2021.

Last reviewed 2021-02-11 · How we verify

NCT04745533: DETAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Contact Study by Antigen Detection Test

Status unknown Last updated 11 February 2021

What this trial tests

trial testing Antigen detection test in SARS-CoV Infection in 3,000 participants. Status unknown.

Timeline

15 February 2021

Primary endpoint
30 April 2021

30 June 2021

Quick facts

Lead sponsor	Juan Fernando Masa Jiménez
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	15 February 2021
Primary completion	30 April 2021
Estimated completion	30 June 2021

Drugs / interventions tested

Antigen detection test

Conditions studied

SARS-CoV Infection — all drugs for SARS-CoV Infection →

Sponsor

Juan Fernando Masa Jiménez

Who can join

18 and older, any sex, with SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stopping the SARS-CoV2 spread is essential to control the pandemic cause by this virus. A great effort is being made to carry out surveillance, case detection and contact control protocols in order to detect and isolate those contagious subjects. Since both symptomatic and asymptomatic subjects can be contagious, a surveillance system based on the presence of symptoms is not enough, requiring to perform diagnostic tests in a large number of subjects, such as asymptomatic contacts or high-prevalence populations, and repeatedly. Moreover, the speed in obtaining results is crucial in order not to delay the isolations of positive subjects. The polymerase chain reaction (PCR) is an expensive test which requires specialized equipment and personnel with a delay in results of 24-48 hours. In addition, its high sensitivity can mean that subjects without infective capacity have a positive result. In contrast, antigen detection tests (ADTs) are cheap and easy to perform, having a result in few minutes. They have shown high sensitivity and specificity in symptomatic subjects, specially in the first week of symptoms when the viral load is high. This could be very useful for the study of asymptomatic contacts to detect those with potential contagiousness quick, easily and cheaply. However, there is no evidence to support the use of ADTs in this group of subjects. For this reason, the investigators propose to carry out a study to compare the diagnostic efficacy of ADTs versus PCR in the group of subjects considered to be close contacts of SARS-Cov2 positive patients in the health area of Cáceres.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

NCT05886816 — Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 · Phase 2 · recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
NCT04579471 — Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study · recruiting

Other Juan Fernando Masa Jiménez trials

Trials by the same sponsor.

NCT04724850 — Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04745533 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juan Fernando Masa Jiménez
Last refreshed: 11 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04745533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing